BioScrip, Inc. (BIOS) reported third-quarter earnings of 14 cents per share, beating the Zacks Consensus Estimate of 10 cents. The company reported earnings of 6 cents in the year-ago period. Although earnings were better than expected, revenues declined 7.2% to $333.5 million. While the specialty business contributed $279 million to revenues, the pharmacy benefit management (PBM) business posted revenues of $54.5 million.   The decline in revenues was mainly due to the elimination of the Medicare Competitive Acquisition Program and the termination of the United Health Group organ transplant and HIV/AIDS contracts. This was partially offset by increased sales of higher margin infusion therapies and other specialty sales.   The company reported a sequential growth of 3% in specialty sales with several therapeutic areas like iron overload, multiple sclerosis (MS), oncology and infusion therapies recording double digit growth from the year-ago period. The oral oncology business should continue ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday October 1st, 2009

DrStockPick.com Stock Report!

**************************************************************

Avis Budget Group, Inc. (NYSE: CAR) announced today that its Avis Budget Rental Car Funding (AESOP) LLC subsidiary has closed its $450 million Series 2009-2 asset-backed term notes. The 5.68% notes were priced to yield 5.75%, have an expected final payment date in February 2013 and are rated Aaa by Moody’s Investors Service.

comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today released the results of a study of changes in search engine marketing in the

...

Micro Imaging Technology, Inc. announced that it has entered into a strategic business development relationship with OPH Ltd. Hong Kong, crucial to securing a manufacturing partner in Asia. OPH will also develop this market for the Micro Imaging Technology (MIT) 1000 Rapid Microbial Identification System by working closely with existing MIT and its distributors to identify and select other strategic partners to expand the company’s business in Asia. MIT recently received Performance Test Method Certification for the Identification of Listeria from the AOAC Research Institute and is now focused on accelerating the commercialization of the MIT 1000.

David Harris, chairman of OPH Ltd. stated, “The MIT 1000 technology is truly a revolutionary development in rapid detection of microbial pathogens. We are very pleased and excited to partner with MIT in delivering these exceptional technological benefits to Asian producers and consumers. The speed, accuracy and cost-savings provided by the MIT 1000 System

...

American Oriental Bioengineering, Inc, (NYSE:AOB) announced today that its fourth quarter 2008 revenues were up a whopping 68% to $96.3 million. Net income for the same period was up 43% to $21.7 million. The good news reflects the continued demand for the company’s pharmaceutical and nutritional products in the Chinese marketplace.

American Oriental, based in China, is engaged in the development and production of plant based products, both pharmaceutical and nutritional. The products are produced from the leaves and roots of various plants. In the case of PBPs (Plant Based Pharmaceuticals), they are used to treat illnesses or associated symptoms and are available in China by prescription and over-the-counter. PBNs (Plant Based Nutraceuticals) are also produced from plant leaves and roots, but are used as preventatives and for general health, and are all sold over-the-counter.

Tony Liu, company Chairman and CEO, commented on the company’s success, in spite of the overall

...

BioScrip, Inc., the specialty pharmacy and pharmacy services provider, had a double dose of good news today with the announcement of exceptional second quarter revenue and earnings figures. Consolidated revenue grew to $348.4 million, an 18.2% increase over the same period last year. Specialty Services revenue shot up to $298.2 million, a 25.3% over the prior year. Even more impressive was quarterly net income, which grew to $1.6 million, compared to $.5 million last year. Net income was helped along by the company’s healthy control over operating expenses, which shrunk as a percentage of revenue to 9.3% from 10.3% over the same period a year ago.

BioScrip’s Chairman and CEO, Richard H. Friedman, stated, “Our second quarter results, including a $3.2 million sequential increase in quarterly operating income, demonstrate our positive sales growth trends and the significant progress we have made toward improving our operating performance. As we work to

...

Sharps Compliance Corp. announced record revenues for the first quarter of fiscal 2009. Revenues jumped 26%, to $4.3 million, from the same quarter last year. Sharps also reported record customer billings of $4.7 million for the quarter, a 30% increase over the same period the year before.

The increase in billings came partly from contracts and patent renewals with pharmaceutical manufacturers, which are expected to continue contributing to billings and revenue growth in fiscal 2009. In addition, customer billings to retail markets increased 23% as a result of strong flu-season demand for the Sharps Disposal By Mail Systems®. There were also higher billings to the professional, commercial, and agricultural markets. The only billing declines were in the healthcare and hospitality markets.

Gross profit was $1.8 million, up 29% over the prior year period. Gross margin was 43.3% in the first quarter of fiscal 2009, a 100 basis point increase compared

...

BioScrip Inc. (Nasdaq: BIOS) is a pharmaceutical healthcare organization that provides medications and management solutions for pharmacies and other related healthcare venues in the United States. The company operates through its Specialty Services and PBM Services segments. As of December 31, 2007, BioScrip operated 40 pharmacies in the United States, including community, mail and infusion pharmacies.

The company recently received a “Buy” rating from Noble Financial, with a price target of $6.50. The firm expects 9.5-10 percent revenue growth, as well as more than 50 percent earnings per share growth over the next three years. BioScrip can achieve this through the likely “significant capture of efficiencies.”

The specialty pharmacy industry is a rapidly growing market, enhanced by its convenient location features across metropolitan areas. For health, transportation or other issues, patients are finding mail delivered prescriptions a quick, cost-effective way to obtain prescriptions.

BioScrip offers both of these services, as well

...

ALR Technologies, Inc. (ALRT.OB) primarily engages in designing, marketing, and distributing medical reminder compliance devices. The company uses technology-based products that aid people in achieving improved health and improved well-being. ALR Technologies is known as a pioneer and leader in the compliance management sector of the disease management industry.

ALR Technologies is focused on providing a product that reminds patients to take their medication or treatment at the prescribed time. The company offers ALRT Med Reminder, ALRT Once-A-Day, ALRT Weekly, ALRT Contact Lens Replacement and ALRT PC200. Each product can be programmed by the user for specific time duration reminders. The company’s well-known product, Constant Health Companion, reminds the user of the time to take medication and it displays the actions or medications necessary to take with that specific reminder. ALR Technologies’ product offering ranges from portability, display on LCD screens, and pet medication reminders.

ALR Technologies is based in Winston-Salem, North

...